 |
|
|
| |
Efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in virologically-suppressed, treatment-experienced and treatment-naïve women with human immunodeficiency virus type 1
|
| |
| |
Reported by Jules Levin
CROI 2018 March 4-7 Boston, MA
Aimee Wilkin1*, Karen Tashima2, Christine Katlama3, Laura Waters4, Ceyhun Bicer5, Donghan Luo6, Eric Y Wong7, Kimberley Brown7
1Wake Forest School of Medicine, Winston-Salem, NC, USA; 2The Miriam Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA; 3HIV Clinical Research Unit, Hopital pitie-Salpetriere, Paris, France; 4University College London Hospital, London, UK; 5BICER Consulting & Research, Antwerpen, Belgium; 6Janssen R&D, LLC, Titusville, NJ, USA; 7Janssen Scientific Affairs, LLC, Titusville, NJ, USA
|
| |
|
|
|
|
|
